Chemotherapy for gastric cancer.

摘要: Metastatic gastric cancer remains a non-curative disease. Palliative chemotherapy has been demonstrated to prolong survival without quality of life compromise. Many single-agents and combinations have confirmed be active in the treatment metastatic Objective response rates ranged from 10-30% for single-agent therapy 30-60% polychemotherapy. Results phase II III studies are reviewed this paper as well potential efficacy new drugs. For patients with localized disease, role adjuvant neoadjuvant radiation is discussed. Most on failed demonstrate advantage, therefore, it not considered standard most centres. Adjuvant immunochemotherapy developed fundamentally Korea Japan. A meta-analysis trials OK-432 suggested that may improve curatively resected cancer. Based results US Intergroup 0116 study, postoperative chemoradiation accepted care North America. However, somewhat confounded by fact underwent less than recommended D1 lymph node dissection pattern recurrence positive effect derived local radiotherapy any micrometastatic disease. Neoadjuvant or experimental, but several showing promising results. Phase needed.